ADXN: AI 评分 44/100 — AI 分析 (4月 2026)

Addex Therapeutics Ltd is a development-stage biopharmaceutical company focused on discovering and developing small-molecule pharmaceuticals for central nervous system (CNS) disorders. The company's research centers on allosteric modulators of G-protein coupled receptors, with lead programs targeting Parkinson's disease, epilepsy, and addiction.

Key Facts: Price: $6.70 AI Score: 44/100 Sector: Healthcare

公司概况

概要：

Addex Therapeutics Ltd, based in Switzerland, is a biopharmaceutical company specializing in the discovery and development of small-molecule allosteric modulators for central nervous system disorders, positioning itself within the competitive biotechnology sector with a focus on unmet medical needs.

ADXN是做什么的？

Founded in 2002, Addex Therapeutics Ltd is a Swiss biopharmaceutical company dedicated to discovering, developing, and commercializing small-molecule pharmaceutical products for central nervous system (CNS) disorders. The company's core focus lies in allosteric modulation, particularly of G-protein coupled receptors (GPCRs), using oral small molecule drugs. This approach aims to create novel treatments for conditions with significant unmet medical needs. Addex's lead programs include Dipraglurant, targeting Parkinson's disease levodopa-induced dyskinesia (LID) and dystonia; ADX71149, for epilepsy and other undisclosed CNS disorders; and GABAB PAM, aimed at treating addiction. Addex operates primarily out of its headquarters in Geneva, Switzerland. The company has established strategic collaborations and licensing agreements with pharmaceutical companies such as Janssen Pharmaceuticals Inc. and Indivior PLC, as well as with organizations like The Charcot-Marie-Tooth Association. These partnerships are crucial for funding research, development, and potential commercialization of its drug candidates. Addex Therapeutics Ltd was originally known as Addex Pharmaceuticals Ltd and rebranded in March 2012 to reflect its evolving focus on therapeutics.

ADXN的投资论点是什么？

Addex Therapeutics presents a high-risk, high-reward investment profile typical of development-stage biopharmaceutical companies. The company's value hinges on the successful clinical development and eventual commercialization of its lead drug candidates, particularly Dipraglurant for Parkinson's disease LID and dystonia. Positive Phase 2b trial results for Dipraglurant could serve as a significant catalyst, potentially leading to increased investor interest and partnership opportunities. However, the company's small size (2 employees) and limited financial resources pose significant risks. The negative profit margin of -4397.0% underscores the company's reliance on external funding and partnerships. The high beta of 1.91 suggests significant volatility relative to the broader market. Investors should carefully weigh the potential upside against the inherent risks associated with drug development and commercialization.

ADXN在哪个行业运营？

Addex Therapeutics operates within the competitive biotechnology industry, which is characterized by high R&D costs, lengthy development timelines, and significant regulatory hurdles. The market for CNS disorder treatments is substantial and growing, driven by an aging population and increasing prevalence of conditions like Parkinson's disease, epilepsy, and addiction. Addex's focus on allosteric modulation offers a potentially differentiated approach compared to traditional drug development methods. Competitors like ADIL, BCLI, CDIO, IBO, and MTNB are also pursuing novel therapies for neurological disorders, creating a dynamic and challenging competitive landscape.

Biotechnology

Healthcare

ADXN有哪些增长机遇？

Expansion of Dipraglurant's Clinical Development: A key growth opportunity lies in advancing Dipraglurant through late-stage clinical trials for Parkinson's disease LID and dystonia. Positive results in Phase 2b trials could unlock significant value, attracting potential partners and paving the way for regulatory approval. The market for Parkinson's disease treatments is projected to reach billions of dollars, offering substantial revenue potential if Dipraglurant proves effective and safe.
Advancement of ADX71149 for Epilepsy: Progressing ADX71149 through clinical trials for epilepsy and other CNS disorders represents another growth avenue. Epilepsy affects millions worldwide, creating a significant market opportunity for novel therapies. Successful development and commercialization of ADX71149 could diversify Addex's product pipeline and revenue streams.
Partnerships and Licensing Agreements: Addex can leverage strategic partnerships and licensing agreements to accelerate drug development and commercialization. Collaborations with larger pharmaceutical companies can provide access to funding, expertise, and global distribution networks. Expanding existing partnerships and forging new alliances will be crucial for Addex's long-term growth.
Expansion into New Therapeutic Areas: Addex could explore expanding its research and development efforts into new therapeutic areas within CNS disorders. Identifying and targeting novel mechanisms and pathways could lead to the discovery of innovative therapies for conditions with unmet medical needs. This diversification strategy could reduce reliance on existing programs and broaden the company's market reach.
GABAB PAM for Addiction Treatment: Developing GABAB PAM for addiction treatment presents a significant growth opportunity. Addiction is a major public health problem with limited treatment options. Successful development and commercialization of GABAB PAM could address a critical unmet need and generate substantial revenue. The addiction treatment market is expected to grow significantly in the coming years, driven by increasing awareness and demand for effective therapies.

Addex Therapeutics focuses on small-molecule allosteric modulators of G-protein coupled receptors (GPCRs) for CNS disorders.
Lead programs include Dipraglurant for Parkinson's disease levodopa-induced dyskinesia (LID) and dystonia.
The company has a negative profit margin of -4397.0%, reflecting its development-stage status and reliance on external funding.
Gross margin is -14.1%, indicating that the cost of revenue exceeds revenue generated.
Beta is 1.91, suggesting higher volatility compared to the overall market.

ADXN提供哪些产品和服务？

Discovers small-molecule pharmaceutical products.
Develops treatments for central nervous system (CNS) disorders.
Focuses on allosteric modulators of G-protein coupled receptors (GPCRs).
Develops oral small molecule drugs.
Targets Parkinson's disease levodopa-induced dyskinesia (LID) and dystonia with Dipraglurant.
Develops ADX71149 for epilepsy and undisclosed CNS disorders.
Develops GABAB PAM for addiction treatment.

ADXN如何赚钱？

Discovers and develops novel drug candidates for CNS disorders.
Out-licenses or partners with larger pharmaceutical companies for clinical development and commercialization.
Generates revenue through licensing fees, milestone payments, and royalties on sales of partnered products.

Pharmaceutical companies (through licensing and collaboration agreements).
Patients suffering from CNS disorders (indirectly, through commercialized drugs).
Healthcare providers (indirectly, through prescription and administration of drugs).

Proprietary allosteric modulation technology platform.
Strong intellectual property protection for drug candidates.
Strategic partnerships with established pharmaceutical companies.
Focus on underserved markets within CNS disorders.

什么因素可能推动ADXN股价上涨？

Upcoming: Phase 2b trial results for Dipraglurant in Parkinson's disease LID and dystonia (timeline: Unknown).
Upcoming: Potential new partnerships or licensing agreements (timeline: Unknown).
Ongoing: Advancement of ADX71149 through clinical trials for epilepsy (timeline: Ongoing).
Ongoing: Continued research and development of GABAB PAM for addiction treatment (timeline: Ongoing).

ADXN的主要风险是什么？

Potential: Clinical trial failures for lead drug candidates.
Potential: Regulatory setbacks and delays.
Ongoing: Limited financial resources and reliance on external funding.
Ongoing: Competition from other pharmaceutical companies.
Potential: Patent expirations and intellectual property challenges.

ADXN的核心优势是什么？

Proprietary allosteric modulation technology.
Focus on CNS disorders with unmet needs.
Strategic partnerships with pharmaceutical companies.
Lead programs in clinical development.

ADXN的劣势是什么？

Limited financial resources.
Small size and limited infrastructure.
Reliance on external funding and partnerships.
High R&D costs and regulatory hurdles.

ADXN有哪些机遇？

Advancement of lead programs through clinical trials.
Expansion into new therapeutic areas.
Strategic collaborations and licensing agreements.
Growing market for CNS disorder treatments.

ADXN面临哪些威胁？

Clinical trial failures.
Regulatory setbacks.
Competition from other pharmaceutical companies.
Patent expirations.

ADXN的竞争对手是谁？

Adial Pharmaceuticals Inc — Focuses on therapies for addiction. — (ADIL)
Brainstorm Cell Therapeutics Inc — Develops cell-based therapies for neurodegenerative diseases. — (BCLI)
Cardio Diagnostics Holdings Inc — Focuses on cardiovascular disease diagnostics. — (CDIO)
IBO Technology Company Limited — Develops and markets IVD products. — (IBO)
Matinas BioPharma Holdings Inc — Develops lipid nanocrystal (LNC) platform technology. — (MTNB)

Key Metrics

Price: $6.70 (+6.35%)
Market Cap: $5.0M
MoonshotScore: 44/100

Company Profile

CEO: Timothy Mark Dyer
Headquarters: Geneva, CH
Employees: 2
Founded: 2020

ADR Level: 2
ADR Ratio: 1:1

常见问题

What does Addex Therapeutics Ltd do?

Addex Therapeutics Ltd is a biopharmaceutical company focused on discovering and developing small-molecule pharmaceuticals for central nervous system (CNS) disorders. The company's core technology revolves around allosteric modulation of G-protein coupled receptors (GPCRs). Their lead programs target conditions like Parkinson's disease, epilepsy, and addiction. Addex aims to create novel treatments by modulating GPCRs, offering a potentially differentiated approach compared to traditional drug development methods. The company primarily operates through partnerships and licensing agreements with larger pharmaceutical firms.

What do analysts say about ADXN stock?

As a development-stage biopharmaceutical company, Addex Therapeutics' stock performance is highly dependent on clinical trial outcomes and regulatory milestones. Given the company's negative profit margin and reliance on external funding, valuation is challenging. Analyst sentiment is likely to be influenced by progress in the company's lead programs, particularly Dipraglurant. Investors should closely monitor clinical trial results and partnership developments to assess the potential upside and downside risks.

What are the main risks for ADXN?

The primary risks for Addex Therapeutics include clinical trial failures, regulatory setbacks, and financial constraints. As a development-stage company, Addex is heavily reliant on the successful development and commercialization of its drug candidates. Clinical trial failures or regulatory delays could significantly impact the company's value. Additionally, Addex's limited financial resources and reliance on external funding pose ongoing risks. Competition from larger pharmaceutical companies with greater resources also presents a challenge.